News Square
Global Crypto News · Real-time Aggregation
📚 Deep Analysis
More →GRVT Burns 1.1 Million Tokens as Countdown to Grvt 2.0 Begins
<strong>[PRESS RELEASE – Singapore, Singapore, October 20th, 2026]</strong> <strong>The discretionary buyback represents close to 1% of circulating supply and precedes four planned product milestones culminating in Grvt 2.0.</strong> <a href="https://grvt.io/" rel="nofollow noopener" target="_blank">>Grvt</a>, a self-custodial trading platform built on its own zero-knowledge (ZK) chain, announced that the Foundation’s token issuer has completed its first GRVT token buyback, purchasing and burning 1.1 million GRVT tokens on the open market. The transaction permanently removed close to 1% of GRVT’s circulating supply at the time of purchase. It marks the first of five milestones ahead of the planned launch of Grvt 2.0 at the end of November 2026. <strong>A Discretionary Buyback with On-Chain Verification</strong> The Foundation’s token issuer intends to conduct further buybacks on a monthly basis. Each transaction remains entirely at the issuer’s discretion, with no predetermined purchase amount or guaranteed schedule. Buybacks are executed through an independent execution partner, with purchased tokens transferred to a designated burn address and permanently removed from circulation. The transactions can be independently verified through the <a href="https://grvt.io/exchange/buybacks" rel="nofollow noopener" target="_blank">>public buyback dashboard</a>, which records the number of tokens purchased and burned, the percentage of circulating supply represented, cumulative burns and on-chain transaction hashes. “The GRVT token is an important part of the ecosystem we are building,” said <strong>Hong, co-founder and CEO of Grvt</strong>. “We welcome the issuer’s buybacks as a demonstration of its long-term commitment to the ecosystem and community. Grvt is expanding its products and markets, and the issuer’s buybacks sit alongside that as a supportive mechanism aimed at reducing circulating token supply.” <strong>Grvt Outlines Four Product Milestones</strong> The announcement follows GRVT’s token generation event in July 2026 and precedes a series of planned launches. <strong>Grvt Earn, scheduled for the End of October,</strong> will introduce yield opportunities backed by tokenized assets, with target yields of up to 11%. Potential returns are expected to derive from underlying asset cash flows, including interest, premiums and invoice-related income. Asset-supplying partners will be announced at launch. Target yields are not guaranteed. <strong>Stable Funding Perps, scheduled for November,</strong> will introduce perpetual futures linked to commodities, stocks, foreign exchange and indices. The contracts are planned to carry zero trading fees and use once-daily funding. Grvt aims to list more than 1,000 markets by the end of December 2026. <strong>Yield as Margin, also scheduled for November,</strong> will allow eligible Grvt Earn balances to support trading positions while continuing to accrue yield, subject to applicable product terms
OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work
OpenAI has bought Orchestra Bio, a San Francisco startup whose AI agents help drug companies keep sprawling development programs on schedule, the ChatGPT maker <a href="https://openai.com/index/openai-to-acquire-orchestra-bio/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>announced Tuesday</a>. “Our goal is to help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner,” OpenAI said in the announcement. Orchestra’s team and platform will be folded into <a href="https://openai.com/rosalind/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>Rosalind</a>, OpenAI’s family of AI models and tools for biologists and chemists. The financial terms were not disclosed. Getting a new medicine from first idea to U.S. approval takes time—up to 15 years according to OpenAI. Every month shaved off that timeline is a month earlier that a new treatment can reach the people waiting for it, and a month earlier that the company can generate cash. The process is also absurdly expensive: bringing one approved drug to market can cost more than <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12668846/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>$2.6 billion</a>, and <a href="https://arxiv.org/pdf/2106.05386" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">fewer than 10%</a> of candidates that enter human testing ever make it to pharmacy shelves. Beyond the science itself, OpenAI says drug teams have to coordinate work across internal departments and outside partners, often relying on systems that don’t talk to each other. Those partners usually include contract research organizations, the outside labs hired to run studies, and contract manufacturers that produce the experimental drug. Orchestra’s AI agents—software that can watch over tasks and flag problems on its own—work out which activities and deadlines take the hit, gather the relevant information and compare ways to respond, while scientists and program leaders make the final call. Founded in the fall of 2022, Orchestra raised its <a href="https://jobs.8vc.com/companies/orchestra/jobs/28818089-senior-software-engineer" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>seed round</a> from Andreessen Horowitz, Definition Capital, Insight Partners, and 8VC, and about $20 million in total, according to <a href="https://www.caplight.com/company/orchestra-bio" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">Caplight data</a>. The company should not be confused with Orchestra BioMed, an unrelated Nasdaq-listed medical device maker that trades under the ticker OBIO. In April, OpenAI launched <a href="https://decrypt.co/364783/openai-gpt-rosalind-drug-discovery-life-sciences-model" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">GPT-Rosalind</a>, a model built specifically for biology and dru
Injective partners with Korean custodian BDACS to launch the KRW1 stablecoin.
CoinWorld news, according to Cointelegraph: Injective has partnered with South Korean custodian BDACS to use its Korean won-backed KRW1 stablecoin as the exclusive settlement asset for tokenized RWAs on its network.
Indonesia's central bank governor: cutting the reserve requirement ratio to 7%.
Bank Indonesia's governor announced that the reserve requirement ratio will be lowered from 9% to 7%.
BlackRock launches new ETF to provide downside protection for Bitcoin investors
Benzinga reports that BlackRock plans to launch a new Bitcoin ETF aimed at providing investors with downside protection. The specific mechanics of how the ETF will operate have not yet been detailed.
Getty Images files for Chapter 11 bankruptcy protection in the U.S. to advance its restructuring plan.
CoinWorld news, Getty Images filed for Chapter 11 bankruptcy protection on Wednesday, formally implementing the restructuring plan it announced more than a week ago as part of the company's privatization process. Last week, Getty announced plans to seek bankruptcy protection, marking a major adjustment for the company after its merger plan with rival Shutterstock fell through due to a heavy debt burden and increasingly fierce competition from AI-generated images. Getty said that affiliates of the Getty family and Koch Equity Development, which has committed up to $533 million in new equity, will hold 100% of the company's equity after the restructuring.
Bank Indonesia keeps its key interest rate at 5.75%, Caixin reported on October 21.
According to a CoinWorld report, Caixin reported on October 21 that Indonesia's central bank kept its key interest rate unchanged at 5.75%.
Fables launches the FABLES token, with market cap falling back to $7.56 million.
CoinWorld news: Fables has announced the launch of its token FABLES, opening points claiming and prologue redemption. Fables' market cap peaked at $18.67 million and currently stands at $7.56 million, down about 59.51% from its post-launch high. Prologue currently has a market cap of $1.38 million, down 57.23% in the past 24 hours. At least 1 Fables can be redeemed for every 40 Prologue.
BlackRock CEO Fink: Slow data center construction will exacerbate inflation.
BlackRock CEO Fink warned that as demand for artificial intelligence (AI) accelerates, delays in data center construction could drive up computing costs and pose a threat to economic growth. He said: "If we don't build these data centers, we will actually exacerbate inflation further, because computing costs are already very high. The faster we build data centers, the more computing power we can provide, and thus the faster we can reduce computing costs." Fink pointed out that slowing the pace of development of this technology would bring broader consequences. He has dismissed concerns about an "AI bubble," believing that the core issue is supply shortage, and stated that demand growth has exceeded expectations. He also warned that if the construction progress of related infrastructure lags, it could ultimately limit people's use of this technology.
Former Japanese Prime Minister Shigeru Ishiba: Takaichi is dishonest in dealing with historical issues.
According to a report by Bijie Network, former Japanese Prime Minister Shigeru Ishiba recently criticized current Prime Minister Sanae Takaichi on a television program, accusing her of being dishonest about historical issues and expressing concern over her political line. On the program, Ishiba said that it was Japan that started the war, causing tens of millions of deaths. He criticized the Takaichi government and the Japanese right wing for being dishonest about historical issues, and said that such a country cannot establish solid diplomatic relations. Ishiba also pointed out that Takaichi claims she wants to make Japan "strong and prosperous," but Japan's gross domestic product may fall to sixth place globally next year, and the so-called "Sanae economics" has not made Japan prosperous. Ishiba said that Takaichi's politics "will not make people happy."